Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...